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Introduction
Psoriasis is an immune-mediated chronic inflammatory disease 
that primarily affects the skin (1); however, in severe forms, pso-
riasis is associated with an increased risk of metabolic syndrome, 
cardiovascular diseases, depression, and decreased life expec-
tancy (2–7). Psoriasis may cause substantial psychological and 
social distress and reduced quality of life (8). Scalp and nail disor-
ders are common symptoms of psoriasis but are often overlooked 
by the treating physician.
The scalp is one of the most common sites involved in patients 
with plaque psoriasis. Scalp psoriasis occurs in 50% to 80% of 
patients with psoriasis, but may also be the sole manifestation 
of disease. Scalp psoriasis may be associated with pruritus, pain, 
and social stigma, and can severely impact quality of life due to 
external exposure (9).
Up to 50% of patients with plaque psoriasis also have concur-
rent nail psoriasis, with an estimated lifetime incidence of 80% 
to 90%. Nail psoriasis occurs more often in patients with severe 
disease, such as those with concomitant psoriatic arthritis. These 
patients have a 70% to 80% prevalence of nail psoriasis. In the 
longer term, nail involvement may be a signal of a more severe 
form of psoriasis or a precursor to psoriatic arthritis (10).
Nail involvement may place a significant burden on patients as 
a result of functional impairment of manual dexterity, pain, and 
psychosocial embarrassment (11). Historically, the nails and the 
scalp are among the most problematic areas to treat. These areas 
are also poorly represented in measures of skin severity, such as 
the Psoriasis Area and Severity Index (PASI), and are usually not 
the focus of therapeutic clinical trials.
Since the approval of biologic agents for treating moderate to 
severe plaque psoriasis, interest has been renewed in revisiting 
unsatisfactory treatment modalities for nail and scalp psoriasis, 
with the goal of finding better treatment options. The clinical 
efficacy and safety of the tumor necrosis factor (TNF) inhibitor 
adalimumab in patients with moderate to severe chronic plaque 
psoriasis have been demonstrated in several randomized, double-
blind, controlled clinical trials; however, data on the effectiveness 
of biologics in treating nail and scalp psoriatic lesions in routine 
clinical practice are scarce (12, 13).
Materials and methods
Study design and patients
This was a multi-center, multi-country, single-arm prospective 
postmarketing study conducted in Slovenia, Hungary, Slovakia, 
Romania, Israel, the Czech Republic, Ukraine, and Estonia. A total 
of 72 dermatological medical centers were included in the study.
Adult patients with moderate to severe plaque psoriasis eligi-
ble for adalimumab therapy (according to the local product label 
and prescription/reimbursement guidelines) with a Nail Psoriasis
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Severity Index (NAPSI) score of the hands and feet of ≥ 10 and a 
Psoriasis Scalp Severity Index (PSSI) score of ≥ 10 were included 
in the study. The decision to treat patients with adalimumab was 
made prior to and independent of participation in this study. Three 
patient populations were analyzed: the full analysis set (FAS), the 
nail psoriasis set (NPS), and the scalp psoriasis set (SPS). The FAS 
included patients with any data available in the case report form 
regarding treatment with adalimumab. The NPS included patients 
from the FAS that had a NAPSI score of the hands and feet of ≥ 10 
at Visit 0 (V0). The SPS included patients from the FAS that had a 
PSSI value of ≥ 10 at V0.
Each patient included in the study was to be observed during 
treatment for a maximum of 12 months. The follow-up visits were 
not interventional and were not strictly scheduled, but rather left 
to the judgment of each investigator. To optimize data collection, 
five patient visits were indicated within the 12-month observation 
period: the baseline visit (V0) and then follow-up visits at months 
3 (V1), 6 (V2), 9 (V3), and 12 (V4).
Objectives
The primary objective of this study was to evaluate the improve-
ment of nail and scalp psoriasis in patients with moderate to se-
vere plaque psoriasis after treatment with adalimumab. The im-
provement of nail psoriasis was measured using the NAPSI and the 
improvement of scalp psoriasis was measured using the PSSI. Sec-
ondary objectives included evaluation of general improvement in 
psoriasis, changes in quality of life, the association between gen-
eral and nail or scalp improvement during adalimumab therapy, 
and the association between general, nail, or scalp improvement 
and patient quality of life. General improvement in psoriasis was 
evaluated using the PASI and changes in quality of life were evalu-
ated using the DLQI. During the study, physical examinations, di-
agnostic measures (erythrocyte sedimentation rate and C-reactive 
protein), and observations were entered into case report forms by 
the investigator or staff.
Statistical analysis
All statistical analyses were carried out using SAS® version 9.2 (SAS 
Institute, Cary, NC, USA) and are described in detail in the respec-
tive statistical analysis plan from July 9th, 2013. Only descriptive 
analyses were performed. For correlation analyses, Spearman’s 
rank correlation coefficient was applied. The analyses presented 
herein are based on all available data. In addition, an analysis 
using the last observation carried forward (LOCF) was used. This 
analysis was based on patients that provided the respective V0 
value and ≥ 1 follow-up assessment. The last of these assessments 
was used for the analysis.
Results
Baseline characteristics
Five hundred six patients were included in the study; however, 
five patients were lost to follow-up after the baseline visit and 
were excluded from the analysis. Of these patients, 157 had nail 
involvement (NPS) and 404 had scalp involvement (SPS), with an 
overlap of 119 patients (NPS and SPS; Fig. 1).
Almost all of the patients in the FAS were Caucasian (99.6%); 
62.7% of the patients were male and the mean age of patients was 
47.0 years. For approximately one-third of the patients in the FAS 
(34.0%), psoriasis was confirmed by biopsy. The mean time since 
diagnosis of psoriasis at V0 was 15.7 years. Concomitant psoriatic 
arthritis was diagnosed in 36.3% of the patients in the FAS.
Efficacy data: primary objectives
The vast majority of patients in the FAS (96.6%) received 40 mg of 
adalimumab every other week without any change in dose during 
the course of the study. The mean value of the NAPSI in the NPS 
at V0 was 13.0 (range, 10–16; 16 is the maximum NAPSI value). 
This mean value decreased during the course of the study to 2.5 at 
V4 (Fig. 2). The mean percentage change in the NAPSI score was 
−81.6% from V0 to V4.
The number of patients with a good clinical response (i.e., 
the rate of patients with an improvement of ≥ 50% in the NAPSI 
score compared with V0 values) increased during the course of 
the study: at V4, 90.4% of patients in the NPS had a good clinical 
response. Complete clearing of the nails (i.e., a NAPSI score of 0) 
was achieved by 40.0% of patients at V4.
The mean PSSI at V0 in the SPS was 26.8 (range, 10–72; 72 is 
Figure 1 | Patient disposition in the study.*
Abbreviations: FAS = full analysis set; NPS = nail psoriasis set; SPS = scalp psoriasis set.
*There was an overlap of 119 patients that were included in both the NPS and the SPS.
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the maximum PSSI value). During the course of the study, the 
mean value decreased to 1.2 at V4 (Fig. 3), yielding a mean per-
centage change of −94.8%. Good clinical response at V4 (i.e., an 
improvement in the PSSI of ≥ 50% compared with values at V0) 
was achieved by 98.3% of all patients. The rate of patients with 
complete clearing of the scalp (i.e., a PSSI of 0) was 71.7% at V4.
Efficacy data: secondary objectives
In the FAS, mean PASI scores decreased from 22.0 at V0 to 1.8 at 
V4. The mean percentage change from V0 to V4 was −91.0% in the 
FAS, −87.4% in the NPS, and −91.5% in the SPS.
An improvement in quality of life was observed during the 
course of the study: the mean DLQI score decreased significantly 
in all patient populations (Table 1). The average improvement in 
quality of life was similar in the SPS and less distinct in the NPS 
compared to the FAS. The percentage of patients in which psoria-
sis had no or only a small effect on quality of life (i.e., DLQI scores 
≤ 5) changed in the FAS from 3.3% at V0 to 94.1% at V4. In the 
NPS, 90.8% of the patients had a DLQI score ≤ 5 at V4; in the SPS, 
the proportion was 94.0% at V4 (Table 2).
Associations between general, nail, or scalp improvement and 
quality of life were evaluated using Spearman’s rank correlation 
coefficient. As a rule of thumb, a correlation coefficient < 0.2 is 
considered as no or only a weak association, between 0.2 and 0.5 
as a moderate association, between 0.5 and 0.8 as a strong as-
sociation, and > 0.8 as a very strong association. The association 
between improvement in quality of life and improvement in nail 
psoriasis in the NPS resulted in moderate to strong correlations 
between 0.25 at V1 and 0.6 at V4-LOCF. The association with the 
improvement of scalp psoriasis in the SPS yielded correlation co-
efficients between 0.49 at V4 and 0.63 at V1 and V2. In the FAS, 
the associations between general improvement of psoriasis and 
improvement in quality of life were strong throughout the study: 
the respective correlation coefficients ranged between 0.69 at V1 
and 0.78 at V4-LOCF.
Safety
Adverse events (AEs) that occurred during the study are presented 
in Table 3. The most common AEs were skin and subcutaneous 
tissue disorders (5.8%) and infections and infestations (1.6%). Se-
rious AEs (SAEs) included exacerbations of psoriasis (n = 4), myo-
cardial infarction (n = 1; the patient died), and lung cancer and 
alcoholic polyneuropathy (n = 1; the patient died). A causal rela-
tionship to the study drug was not indicated in any of the patient 
deaths. One patient had a SAE of psoriasis that was considered 
to be probably related to treatment by the investigator. No new 
clinical concerns were established with regard to the incidence of 
adverse drug reactions and no new safety signals were observed.
Discussion
Nail psoriasis is notoriously difficult to treat because nails are 
slow to heal and conventional treatments are generally difficult to 
administer, are considered inconvenient by patients, are limited 
by AEs, and often lose efficacy over time. Overall, there is no con-
sistent treatment approach to nail psoriasis. There is also a lack 
of controlled study data related to existing treatment modalities. 
Relatively effective conventional systemic treatments for nail pso-
riasis (cyclosporine, methotrexate, and acitretin) have a serious 
toxicity potential (10). Treatment of scalp psoriasis is even less 
well established. All conventional topical therapies are difficult 
to administer and affect the cosmetic hair condition, resulting in 
reduced patient compliance. In patients with recalcitrant scalp 
changes, systemic immunosuppressive therapy is recommended; 
however, the toxicity of these drugs limits their long-term use (9). 
Despite the fact that biologics have been used for more than a dec-
ade in the treatment of various forms of psoriasis, data on the ef-
ficacy and safety of these drugs in the treatment of scalp and nail 
psoriasis are rather limited. A few case reports can be found in 
the literature; however, there are no published data from non-in-
terventional studies (9, 10), such as postmarketing observational 
studies, reflecting data on routine clinical practice.
The results of this study clearly indicate the beneficial effect of 
Figure 2 | Mean NAPSI scores through the course of the study.
Abbreviations: NAPSI = Nail Psoriasis Severity Index.
Figure 3 | Mean PSSI scores through the course of the study.
Abbreviations: PSSI = Psoriasis Scalp Severity Index.
Table 1 | Change in quality of life with respect to DLQI (metrical).
FAS NPS SPS
V0 V4 % change V0 V4 % change V0 V4 % change
Mean DLQI
score 20 1.5 −91.2% 20.2 2.2 −87.7% 20.6 1.5 −92.2%
Abbreviations: DLQI = Dermatology Life Quality Index; FAS = full analysis set; 
NPS = nail psoriasis set; SPS = scalp psoriasis set.
Table 2 | Change in quality of life with respect to DLQI (dichotomous).
DLQI* score FAS NPS SPSV0 % V4 % V0 % V4 % V0 % V4 %
≤ 5 3.3 94.1 4.3 90.8 1.6 94.0
> 5 96.7 5.9 95.7 9.2 98.4 6.0
Abbreviations: DLQI = Dermatology Life Quality Index; FAS = full analysis set; 
NPS = nail psoriasis set; SPS = scalp psoriasis set.
*A DLQI score of 0 to 5 means no effect or a small effect on patient quality of life.
Table 3 | Overview of AEs
Type of event N %
Any AE 48 9.6
Serious AE 5 1
Adverse drug reaction* 30 6
AE leading to drug withdrawal 35 7
Abbreviations: AE = adverse event.
*AE with a causal relationship to the study drug judged as possible or probable.
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adalimumab with regard to the primary objective: improvement of 
scalp and nail psoriasis after 12 months of treatment. In 90% of 
patients, no additional anti-psoriatic medication was taken during 
the observation time.
Data on the effectiveness of adalimumab are in accordance with 
results of several previous studies, including the open-label STE-
REO study, describing a pronounced improvement in patients with 
nail psoriasis treated with adalimumab (12), and the randomized, 
controlled BELIEVE study, which reported the effectiveness of 
treatment for scalp psoriasis as a secondary outcome (13). In the 
BELIEVE study, the mean NAPSI score at baseline was 25.3 (in this 
study, the mean score was 13.0), and the mean PSSI score was 16.3 
(in this study, the mean score was 26.8), suggesting a more severe 
scalp affliction in this study (comparisons with regard to the NAP-
SI score are hard to draw). Overall, improvement in disease scores 
correlated well with improvement in quality of life. The average 
improvement in the NPS was slightly less pronounced compared 
with the overall population for both indications, suggesting that 
nail psoriasis may be more recalcitrant to treatment. The favorable 
association of the effects of adalimumab with general quality of 
life ratings has been režported previously, further supporting the 
results of this study in routine dermatological practice (14–16). Al-
though data from an observational study are of a lower evidence 
level than data retrieved from a randomized clinical trial, data 
gleaned from general dermatological practice more readily allow 
generalization and deductions for the real-world treatment of pa-
tients with psoriasis.
Adalimumab appears to be an effective treatment for scalp and 
nail psoriasis in patients with moderate to severe plaque psoria-
sis, improving both objective clinical indices (NAPSI and PSSI) 
and patients’ quality of life. No new clinical concerns were estab-
lished and no new safety signals were observed in the study. This 
observational study provides the rationale for further randomized 
clinical trials in the quest for an improved treatment regimen in 
patients with nail and scalp psoriasis.
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